Just some weekend reading
Biotech Valuation Idiosyncrasies and Best Practices
Biotech companies with little to no revenue can still be worth billions. Consider the most prominent 2017 biotech M&A deal when Gilead bought Kite Pharma for almost $12 billion. At the time of the deal, Kite had over $600 million in accumulated deficit, but it also had a pipeline of CAR-T cell therapies, which treat cancer
https://www.toptal.com/finance/valuation/biotech-valuation
Industry news, page-1513
-
- There are more pages in this discussion • 252 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.71 |
Change
0.010(0.59%) |
Mkt cap ! $291.1M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.75 | $1.70 | $226.9K | 131.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9599 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 4886 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |